New drug combo shows promise in early esophageal cancer trial
NCT ID NCT06654297
First seen Apr 02, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This early-phase study tests whether giving two drugs—camrelizumab and palbociclib—before surgery is safe and feasible for people with a type of esophageal cancer that can be removed. The trial involves 6 participants and focuses on side effects and whether the treatment delays surgery. It is not a cure, but aims to improve cancer control before the main operation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.